According to the U.S. National Institutes of Health, nearly 240,000 clinical trials were registered as of February 2017, comprising all 50 U.S. states and 195 countries. More strikingly, over half of these studies included global (i.e., non-U.S.) sites. Global clinical trial sites tend to be more than geographically disparate: sites are also culturally distinct, differently regulated and at the mercy of unique transportation networks and infrastructures. While the benefits of worldwide studies have been appreciated for decades, the implications are still not fully understood among many study sponsors. Typically, within sponsor organizations, the best perceived solution to globalization has been to scale commodity sourcing and procurement processes. However, the commodity procurement approach fails to accommodate the full scope of management challenges presented by multi-site, multi-country protocol designs. These challenges pertain not only to procurement, but also to efficiency, compliance, distribution, privacy, ethics, and budget. The value and benefits of a systemic alternative, called Clinical and Ancillary Supply Chain Management, is explored herein.
Ancillare was founded on the belief that a better way to deliver clinical and ancillary supplies to the thousands of sites
conducting trials each day would change the industry. Our Executive Leadership Team lives our mission through contributing to the greater research community — with their time and advocacy.
This past weekend, Ancillare’s EVP, Global Clinical Development, Gurinder Shinmar completed the Marsden March in Great Britain. The Marsden March is a 14 mile and 5 mile charity walk. It runs between The Royal Marsden hospitals in Chelsea and Sutton.
The organization is committed to ensuring the nurses, doctors, and research teams can provide the very best care and develop life-saving cancer treatments, which are used in the UK and around the world. From funding state-of-the-art equipment and groundbreaking research, to creating the best patient environments, Marsden continues to explore ways to improve the lives of people affected by cancer.
Shinmar said of the experience, “I decided to participate in the Marsden March because — like so many others — my family has suffered the loss of a loved one who succumbed to cancer. The Royal Marsden Hospital is, in my view, truly an academic centre of excellence. The work the hospital does is critical in term of discovering the next cancer therapies, whilst at the same time providing exemplary care and support to patients and their families. I’m proud that Ancillare can play such a pivotal role in facilitating clinical trials, including oncology studies, with the view to discover new life saving pharmacotherapies.”